Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG for clinical development. For example, we have...
Saved in:
Main Authors: | Wen-Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, Paul J. Carter |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2362789 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Human adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses
by: Zhenwei Liu, et al.
Published: (2025-01-01) -
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024-12-01) -
Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01) -
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024-12-01) -
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)